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Type 1 diabetes is ametabolic disease caused by autoimmunity towards𝛽-cells. Different strategies have been developed to restore𝛽-
cell function and to reestablish immune tolerance to prevent and cure the disease. Currently, there is no effective treatment strategy
to restore endogenous insulin secretion in patients with type 1 diabetes. This study aims to restore insulin secretion in diabetic
mice with experimental antigen-specific immunotherapy alone or in combination with rapamycin, a compound well known for its
immunomodulatory effect. Nonobese diabetic (NOD) mice develop spontaneous type 1 diabetes after 12 weeks of age. Autologous
tolerogenic dendritic cells—consisting in dendritic cells pulsed with islet apoptotic cells—were administered to diabetic NODmice
alone or in combinationwith rapamycin.The ability of this therapy to revert type 1 diabetes was determined by assessing the insulitis
score and bymeasuring both blood glucose levels andC-peptide concentration.Our findings indicate that tolerogenic dendritic cells
alone or in combination with rapamycin do not ameliorate diabetes in NOD mice. These results suggest that alternative strategies
may be considered for the cure of type 1 diabetes.
1. Introduction
Type 1 diabetes (T1D) results from the autoimmune destruc-
tion of insulin-producing 𝛽-cells in the pancreatic islets of
Langerhans [1]. The prevalence of this disease, its compli-
cations, and the lack of effective curative and preventive
strategies call for a significant effort to find means to restore
the tolerance to 𝛽-cells as the best way to control this disease.
Recently, we reported a new experimental immunotherapy
protocol based on the use of dendritic cells (DCs) loadedwith
islet apoptotic cells. This protocol clearly reduces T1D inci-
dence and insulitis in non-obese diabetic mice (NOD) [2].
TheNODmouse strain is an excellentmodel for autoimmune
diabetes.
A limited number of treatments were demonstrated to
revert established diabetes in NOD mice [3, 4]. Given the
preventive effectiveness of DCs loaded with islet apoptotic
cells, we tested whether this immunotherapy is able to reverse
diabetes. To improve this treatment, we also combined
tolerogenic DCs with rapamycin, an immunosuppressant
that inhibits the response to IL-2 and thereby blocks the
activation of T and B lymphocytes.
Rapamycin, a noncalcineurin-based inhibitor, was used
to prevent acute graft rejection following allogeneic trans-
plantation [5] and helps to expand T regs [6]. Therefore, we
hypothesized that the administration of rapamycin prior to
immunotherapy might help to reduce insulitis in diabetic
mice, thus facilitating the subsequent action of antigen
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specific immunotherapy. Our findings indicate that tolero-
genic DCs do not ameliorate diabetes in NOD mice in terms
of blood glucose levels, endogenous insulin secretions, or
insulitis score. Surprisingly, therapy with rapamycin does
not improve the metabolic conditions in mice treated with
tolerogenic DCs.
2. Materials and Methods
2.1. Animals. This study was carried out in strict accordance
with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the Generalitat de Catalunya,
Catalan Government. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the
Germans Trias i Pujol Research Institute (Permit number:
DAAM 5157). Wild type NOD mice were obtained from our
colony established with mice from the Jackson Laboratory
(Bar Harbor, ME, USA). Mice were kept under specific
pathogen-free conditions and monitored daily for diabetes
assessment. Mice with glycosuria were confirmed diabetic
when either successive blood glucose levels were higher than
200mg/dL, or when a measure was higher than 360mg/dL.
Mice were treated with daily s.c. insulin (1U, Insulatard Flex-
Pen, Novo-Nordisk, Bagsvaerd, Denmark). Diabetic NOD
mice (12- to 17-weeks old) were divided into four groups:
(1) sham (nontreated control group), (2) Rapa (treated with
rapamycin), (3)NITApo-DCs (treatedwith tolerogenicDCs),
and (4) Rapa + NITApo-DCs (treated with rapamycin and
tolerogenic DCs). A total of 3–6 animals were included in
each group. Sham group animals were injected with 0.15mL
physiological saline solution. Mice were monitored for urine
glucose using Glucocard strips (Menarini, Barcelona, Spain)
daily for 30 days. Blood glucose levels were monitored
weekly (AccuCheck, Roche Diagnostics, Indianapolis, IN)
after fasting for 2 hours. Blood was collected for C-peptide
assay at the end of the follow-up.
2.2. Treatment with Tolerogenic Dendritic Cells. DCs were
propagated from bone marrow progenitors of female wild
type NOD mice in a culture medium containing GM-CSF
(Prospec, Rehovot, Israel) as previously described [2]. At
the same time, in vitro cultured NIT-1 cells obtained from
the American Type Culture Collection (ATCC, Manassas,
VA) and derived from 𝛽-cells from NOD/Lt mice [7] were
submitted to apoptosis by UVB irradiation, as described [2].
Tolerogenic DCswere prepared by coculturingDCswith islet
apoptotic bodies in a 3 : 1 ratio for 2 hours. DCs loaded with
apoptotic bodies from NIT-1 cells (NITApo-DCs) were sepa-
rated from unloaded DCs by sorting (FACSAria II, BD Bio-
sciences). NIT-1 cells were prelabelled with CFSE (Molecular
Probes, Invitrogen, Carlsbad, CA) to allow the separation of
DCs pulsedwith apoptotic bodies (CD11c andCFSEpositive).
Diabetic NOD mice were given a single intraperitoneal dose
of 106 NITApo-DCs (NITApo-DCs group) in 150 𝜇L saline
solution, seven days after the onset of the disease.
2.3. Treatment with Rapamycin. Treatment with rapamycin
(Rapamune, Pfizer Inc, Bedminster, NJ) was orally adminis-
tered at the clinical onset of diabetes. Rapamycin was diluted
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Figure 1: Immunotherapy—alone or in combination with
immunosuppressant—does not reverse T1D in NODmice. Glucose
levels in diabetic mice from different groups.White bar corresponds
to glycaemia in a group of 8 mice at the onset of the disease. Black
bars correspond to different groups at the end of the study (day 30).
No significant differences were observed when treated groups were
compared to the sham group. Significant differences were found
when the NITApo-DCs group was compared with mice treated
with rapamycin (Rapa) and with mice treated with tolerogenic DCs
and rapamycin (Rapa + NITApo-DCs). Results are means ± SD
from 3–6 mice per group. ∗ and ∗∗ mean significant differences,
𝑃 < 0.05 and 𝑃 < 0.01, respectively.
in water. During the first week, rapamycin was administered
once daily at a dose of 2.5mg/kg by gavage (gauge 20G, Fine
Science Tools, Foster City, CA). After the administration of
immunotherapy at day 7, rapamycin was given in alternate
days until the endof the follow-up (30 days) (Rapa+NITApo-
DCs group). A control group receiving rapamycin, but not
immunotherapy with DCs, was also included (Rapa group)
in the study.
2.4. Insulitis Score. The degree of islet infiltration by
leukocytes—insulitis—was determined at the end of the
study. Briefly, the pancreases from all the animals of each
group were snap frozen in an isopentane/cold acetone bath.
Cryosections of 5 𝜇m were obtained at five nonoverlapping
levels, stained with hematoxylin and eosin (H&E), and
analyzed by two independent observers who were blinded
to the experimental conditions. Each observer assessed a
minimum of 40 islets per animal. Insulitis was scored as
described elsewhere [2]: 0, no insulitis; 1, peri-insular; 2, mild
insulitis (<25% of infiltrated islets); 3, severe insulitis (25–
75%of infiltrated islets); 4, destructive insulitis (complete islet
infiltration).
2.5. Endogenous Insulin Production. The recovery of 𝛽-cell
function was assessed by measuring C-peptide levels in sera
at the end of the study, after fasting for 2 hours. The C-
peptide concentration (pg/mL) was determined by ELISA
(Raybiotech, Norcross, GA). The sensitivity of the assay is
772 pg/mL. Reproducibility Intra-Assay: CV < 10% and
Inter-Assay: CV < 15%.This ELISA shows no cross-reactivity
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Figure 2: Insulitis is not reduced by immunotherapy and/or rapamycin administration in diabetic NOD mice. Effect of the treatment with
tolerogenic DCs and/or an immunosuppressant (rapamycin) on insulitis in NOD mice. (a) Insulitis score for different groups. The pancreas
from 3 animals/group was analyzed by two independent observers at the end of the study period (30 weeks). Each observer assessed a
minimum of 40 islets per animal. Results are means ± SD. (b) The percentage of classified islets in each of the five infiltration categories
in different groups was as follows: 0, no insulitis; 1, peri-insulitis; 2, mild insulitis (<25% of infiltrated islets); 3, severe insulitis (25–75% of
infiltrated islets); 4, destructive insulitis (complete islet infiltration).
with any of the cytokines tested: ghrelin, nesfatin, angiotensin
II, NPY, and APC.
2.6. Statistical Analysis. The results were expressed as aver-
ages of each group ± standard deviation (SD). The compar-
isons between groups used the unpaired 𝑡-test for unpaired
data after confirming normal distributions. A 𝑃-value < 0.05
was considered significant.
3. Results
3.1. Tolerogenic DCs—Alone or in Combination with
Rapamycin—Do Not Reverse T1D in NOD Mice. Mice
were spontaneously rendered diabetic after 13 weeks
of age showing elevated blood glucose concentration
(363.5 ± 109.6mg/dL, mean ± SD). To assess the efficacy of
tolerogenic DCs for curing T1D we treated diabetic NOD
mice seven days after the onset of the disease. Fasting blood
glucose levels were not significantly different between mice
treated with NITApo-DCs immunotherapy and the sham
group at the end of the study (Figure 1). The administration
of rapamycin did not improve glycaemia when compared
to the sham group. Moreover, no effect in glucose levels
was observed with the combination of both agents, with
or without immunosuppression. Among the three treated
groups, the lowest glycaemia was achieved by mice treated
with tolerogenic DCs, showing significant differences when
compared to mice treated with rapamycin alone or in
combination with tolerogenic DCs. However, all diabetic
NOD mice sustained hyperglycaemia at the end of the study.
3.2. Insulitis Is Not Reduced by Tolerogenic DCs in Diabetic
NOD Mice. Insulitis was scored in diabetic mice 30 days
after treatment to determine the islet leukocytic infiltration
degree. No significant differences were found between the
four groups of diabetic mice (Figure 2(a)). The insulitis score
in mice treated with tolerogenic DCs-based immunotherapy
was similar to that in the sham group. The insulitis score in
mice treated with rapamycin in combination of tolerogenic
DCs was similar to that in mice treated with rapamycin
alone. The percentage of islets classified in each of the five
infiltration categories in different groups showed that the
severity of insulitis correlates with the percentage of islets
with destructive insulitis and severe insulitis (Figure 2(b)).
Insulitis-free islets were less than 30% in groups of diabetic
mice.
3.3. Endogenous Insulin Secretion Ameliorates in Mice Treated
with Rapamycin but the Effect Is Counteracted When Com-
bined with Tolerogenic DCs. SerumC-peptide levels reflected
pancreatic insulin contents. To determine the recovery of 𝛽-
cell function, C-peptide concentrations in sera were deter-
mined at the end of the study. No significant differences
were observed when compared mice treated with tolerogenic
DCs to mice from the control sham group. Treatment with
rapamycin increases insulin secretion in NOD mice: C-
peptide levels were significantly higher in mice treated with
rapamycin when compared to those in the sham group,
𝑃 < 0.05. However, C-peptide levels in mice treated with
tolerogenic DCs or simultaneously treated with tolerogenic
DCs-based immunotherapy and rapamycin were similar to
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Figure 3: Endogenous insulin secretion ameliorates in mice treated
with rapamycin but the effect is counteracted when combined with
tolerogenic DCs. Serum C-peptide levels determined by ELISA at
the end of the follow-up (30 days). Data from 3–6 animals/group are
expressed as means ± SD. ∗Means significant differences, 𝑃 < 0.05.
those in the sham group (Figure 3) and significantly lower
than those in mice treated with rapamycin (𝑃 < 0.05).
4. Discussion
The NOD mouse model has proven to be an important tool
for the study of new therapeutic targets and preclinical studies
in T1D. More than 200 immune interventions have been
described to prevent diabetes in NOD mice [8, 9] and a few
have restored insulin secretion.
In a previous work we demonstrated that immature
DCs pulsed with apoptotic islet cells prevent T1D in NOD,
correlating with significant reductions of insulitis, costimula-
tory signals and the secretion of proinflammatory cytokines
[2]. T1D prevention was achieved using DCs loaded with
apoptotic islet cells, but not with apoptotic bodies from other
cell type or unloaded DCs, thus demonstrating the antigenic
specificity of immunotherapy.
Therefore, the aim of this study was to reverse diabetes
in diabetic mice by administering this immunotherapy. Since
the focus of the study was to reverse diabetes and no effects
were observed using tolerogenic DCs, we included a group
of mice simultaneously treated with tolerogenic DCs and
rapamycin. The lack of effect of the tolerogenic DCs-based
immunotherapy in ameliorating endogenous insulin secre-
tion, even when an immunosuppressant was administered to
diabetic mice, could be due to several factors. On the one
hand, the stage of insulitis at the time of immunotherapy
administration was very severe, thus hindering the recovery
of beta cell mass. On the other hand, the design of the
immunotherapy (which was optimal for the prevention of the
disease) could not have been appropriate for diabetes reversal.
The amount of DCs and the number of doses could be too low
for recovering endogenous insulin secretion.
Surprisingly, rapamycin does not improve the effects of
immunotherapy in NOD mice. Immunosuppressants have
been reported to impair human 𝛽-cell function and survival
[10] and for that reason these agents have not any effect in
ameliorating insulin secretion. This is in contrast to data
in prediabetic NOD mice wherein rapamycin significantly
protected animals from disease development but did not
reverse the course of the disease after T1D onset [11, 12].
However, rapamycin combined with other experimental
immunotherapies that successfully prevent and cure T1D
(e.g., anti-CD3- antibodies) [13] exerts a detrimental effect on
disease outcome for as long as it is administered [14].
Our results showed a significant decrease in glycaemia
in mice treated with tolerogenic DCs when compared to
mice treated with rapamycin alone or in combination with
tolerogenic DCs. However, all diabetic mice were hypergly-
caemic during the follow-up and daily injections of insulin
were required for survival. Although the differences are not
significant, the lower insulitis score values achieved in our
study correspond to mice treated with rapamycin alone or
in combinationwith tolerogenic DCs-based immunotherapy.
This drug seems to have an effect in a tendency to decrease
insulitis, as expected for an immunosuppressor agent. We
also observed that endogenous insulin secretion ameliorates
in mice treated with rapamycin. However, when combined
with tolerogenicDCs, the effect of rapamycin is counteracted,
thus indicating that the combination of immunosuppressants
with tolerogenic DCs does not increase the ability of tolero-
genic DCs to recover insulin secretion in NODmice.
5. Conclusion
In conclusion, immunotherapy with tolerogenic DCs alone
or in combination with the immunosuppressant rapamycin
has no effects on restoring insulin secretion in diabetic NOD
mice. We believe that immunotherapy for curing T1D must
be a combination of agents, dampening inflammation, re-
establishing peripheral immunological tolerance, and helping
islet regeneration to recover 𝛽-cell mass.
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